Drug Profile
Research programme: adenosine receptor antagonists - Merck/ Domain Therapeutics
Alternative Names: immuno oncology therapeutics - Merck/Domain TherapeuticsLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Domain Therapeutics; Merck KGaA
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Purinergic P1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in France
- 28 Dec 2021 No recent reports of development identified for research development in Cancer in Germany
- 28 Feb 2021 No recent reports of development identified for research development in Cancer in France